CASTOR: Daratumumab Added to Bortezomib/Dexamethasone Improves PFS, Response in RR Myeloma

June 3-7, 2016; Chicago, Illinois
The investigators of this randomized phase III trial suggest that adding daratumumab to bortezomib/dexamethasone should be considered as a new standard of care for patients with relapsed/refractory multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 564 KB
Released: June 8, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Commentary from Dr Julie M. Vose on how to select therapy for patients with diffuse large B-cell lymphoma, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 1, 2021

person default Ashley Leak Bryant, PhD, RN, OCN, FAAN Sara Tinsley, PhD, APRN, AOCN Released: November 29, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue